|
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy. From Wikipedia under the
GNU Free Documentation License  abatacept.info 584px x 556px | 38.10kB [source page] see chain abatacept info jpg Image file link  img.medscape.com 337px x 450px | 42.80kB [source page] Close window slide 7 Abatacept or Infliximab 6 and 12 Month Efficacy ACR and HAQ Responders  img.medscape.com 337px x 450px | 57.50kB [source page] Close window slide 16 Abatacept CTLA 4 Human IgG1 Fc Protein From Yahoo Image Search: "Abatacept"  king5.com Thu, 15 Jul 2010 00:56:55 GMT+00:00 KING5.com He's getting monthly infusions of an arthritis drug called Abatacept . The drug keeps Daniel's immune system from killing the insulin-producing cells he has ... New drug may manage diabetes, shed kilos Sydney Morning Herald New pill to flush away diabetes Adelaidenow Discovery could aid in future diabetes therapy Corvallis Gazette Times  biomedreports.com Thu, 08 Jul 2010 01:00:45 GMT+00:00 BioMedReports (subscription) (blog) Bristol-Myers Squibb Company (NYSE: BMY) has today announced that on 1 July 2010 the European Commission approved a new indication for orencia ( abatacept ), ...  bclocalnews.com Wed, 07 Jul 2010 06:18:40 GMT+00:00 Terrace Standard My grandma gets to try this new medication Abatacept that could let her walk easier and improve day-to-day tasks such as getting dressed and climbing stairs ... From Google News Search: "Abatacept"  medciclopedia.com Dr. Arce Mon, 26 Oct 2009 09:24:43 GM Abatacept. (Orencia) es efectivo contra los sintomas clinicas y erosion articular en artritis reumatoide temprana por al menos dos anos, de acuerdo a dos.  biotech-finances.com Copyright Biotech Finances ue, 20 Oct 2009 13:17:01 GM Oct. 20, 2009 12:00 UTC New Data Describe Safety of Subcutaneous Administration of orencia (. abatacept. ) For Pat ...  sciencenerddepot.com Administrator Mon, 26 Dec 2005 13:32:03 GM bristol-myers squibb company (nyse: bmy) announced today that the us food and drug administration (fda) has approved orencia (. abatacept. ), the first selective modulator of a co-stimulatory signal required for full t-cell activation, ... From Google Blog Search: "Abatacept" |
